6 October 2020
Appendix 2A
6 October 2020
Cleansing Notice
5 October 2020
Change in Director's Interest Notice - R Thomas
5 October 2020
Change in Director's Interest Notice - J Fairley
30 September 2020
Investor Presentation
30 September 2020
Starpharma completes oversubscribed A$45M placement
30 September 2020
Proposed issue of Securities
28 September 2020
Trading halt
25 September 2020
VivaGel® BV secures TGA approval for prevention of BV
23 September 2020
2020 Annual General Meeting
23 September 2020
Appendix 2A
18 September 2020
Change in substantial holding
17 September 2020
Change in substantial holding
17 September 2020
Starpharma to present at OTCQX Life Sciences Investor Forum
14 September 2020
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
3 September 2020
Change in substantial holding
3 September 2020
Starpharma awarded $1M MRFF funding for COVID-19 spray
1 September 2020
SPL creates slow release soluble DEP® remdesivir nanoparticle
1 September 2020
Change in substantial holding
27 August 2020
Annual report and full year financial results

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.